Results of univariate and multivariate analysis of NRM among 738 patients with Ph+ ALL
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR (95% Cl) . | P . | RR (95% Cl) . | P . | |
| Imatinib use before SCT | ||||
| No | 1 (Reference) | 1 (Reference) | ||
| Yes | 0.65 (0.49-0.88) | <.001 | 0.55 (0.37-0.83) | .005 |
| Age at SCT (years) | ||||
| ≤29 | 1 (Reference) | 1.03 (1.02-1.05) | <.001 | |
| 30-54 | 1.77 (1.16-2.70) | .008 | (Regression) | |
| ≥55 | 2.54 (1.51-4.30) | <.001 | ||
| HLA disparity | ||||
| Matched | 1 (Reference) | 1 (Reference) | ||
| Mismatched | 1.15 (0.86-1.54) | .330 | 1.27 (0.87-1.87) | .219 |
| Stem cell source | ||||
| Related bone marrow | 1 (Reference) | 1 (Reference) | ||
| Unrelated bone marrow | 1.47 (1.01-2.13) | .044 | 1.32 (0.76-2.32) | .327 |
| Related peripheral blood | 1.37 (0.87-2.14) | .174 | 1.55 (0.95-2.53) | .081 |
| Cord blood | 1.49 (0.93-2.38) | .097 | 1.59 (0.81-3.11) | .181 |
| PS at SCT | ||||
| 0 | 1 (Reference) | 1 (Reference) | ||
| 1-4 | 1.04 (0.76-1.42) | .810 | 0.90 (0.64-1.26) | .542 |
| Days from diagnosis to SCT | ||||
| >180 days | 1 (Reference) | 1 (Reference) | ||
| ≤180 days | 1.60 (1.20-2.13) | .001 | 1.35 (0.97-1.88) | .075 |
| BCR-ABL subtype | ||||
| Major | 1 (Reference) | 1 (Reference) | ||
| Minor | 1.20 (0.40-3.62) | .750 | NA | |
| Major and minor | 0.96 (0.33-2.76) | .940 | NA | |
| Donor recipient gender match | ||||
| Male-male | 1 (Reference) | 1 (Reference) | ||
| Male-female | 0.83 (0.55-1.25) | .380 | 0.73 (0.48-1.12) | .150 |
| Female-male | 1.01 (0.67-1.51) | .970 | 1.07 (0.71-1.62) | .737 |
| Female-female | 0.95 (0.63-1.42) | .790 | 0.85 (0.55-1.30) | .446 |
| Conditioning regimen | ||||
| Reduced intensity | 1 (Reference) | 1 (Reference) | ||
| Myeloabrative | 0.76 (0.44-1.31) | .328 | 0.93 (0.52-1.67) | .819 |
| WBC at diagnosis | ||||
| <30 000/μL | 1 (Reference) | 1 (Reference) | ||
| ≤30 000/μL | 1.04 (0.78-1.38) | .810 | 1.03 (0.94-1.14) | .468 |
| GVHD profiraxis | ||||
| CyA/MTX | 1 (Reference) | 1 (Reference) | ||
| Tacrorimus/MTX | 1.19 (0.89-1.60) | .250 | 1.23 (0.84-1.81) | .287 |
| Cytogenetics | ||||
| t(9;22) only | 1 (Reference) | 1 (Reference) | ||
| Other abnormality | 1.03 (0.68-1.54) | .900 | NA | |
| ABO blood type disparity | ||||
| Match | 1 (Reference) | 1 (Reference) | ||
| Minor | 1.31 (0.89-1.92) | .170 | NA | |
| Major | 1.28 (0.91-1.82) | .160 | NA | |
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| RR (95% Cl) . | P . | RR (95% Cl) . | P . | |
| Imatinib use before SCT | ||||
| No | 1 (Reference) | 1 (Reference) | ||
| Yes | 0.65 (0.49-0.88) | <.001 | 0.55 (0.37-0.83) | .005 |
| Age at SCT (years) | ||||
| ≤29 | 1 (Reference) | 1.03 (1.02-1.05) | <.001 | |
| 30-54 | 1.77 (1.16-2.70) | .008 | (Regression) | |
| ≥55 | 2.54 (1.51-4.30) | <.001 | ||
| HLA disparity | ||||
| Matched | 1 (Reference) | 1 (Reference) | ||
| Mismatched | 1.15 (0.86-1.54) | .330 | 1.27 (0.87-1.87) | .219 |
| Stem cell source | ||||
| Related bone marrow | 1 (Reference) | 1 (Reference) | ||
| Unrelated bone marrow | 1.47 (1.01-2.13) | .044 | 1.32 (0.76-2.32) | .327 |
| Related peripheral blood | 1.37 (0.87-2.14) | .174 | 1.55 (0.95-2.53) | .081 |
| Cord blood | 1.49 (0.93-2.38) | .097 | 1.59 (0.81-3.11) | .181 |
| PS at SCT | ||||
| 0 | 1 (Reference) | 1 (Reference) | ||
| 1-4 | 1.04 (0.76-1.42) | .810 | 0.90 (0.64-1.26) | .542 |
| Days from diagnosis to SCT | ||||
| >180 days | 1 (Reference) | 1 (Reference) | ||
| ≤180 days | 1.60 (1.20-2.13) | .001 | 1.35 (0.97-1.88) | .075 |
| BCR-ABL subtype | ||||
| Major | 1 (Reference) | 1 (Reference) | ||
| Minor | 1.20 (0.40-3.62) | .750 | NA | |
| Major and minor | 0.96 (0.33-2.76) | .940 | NA | |
| Donor recipient gender match | ||||
| Male-male | 1 (Reference) | 1 (Reference) | ||
| Male-female | 0.83 (0.55-1.25) | .380 | 0.73 (0.48-1.12) | .150 |
| Female-male | 1.01 (0.67-1.51) | .970 | 1.07 (0.71-1.62) | .737 |
| Female-female | 0.95 (0.63-1.42) | .790 | 0.85 (0.55-1.30) | .446 |
| Conditioning regimen | ||||
| Reduced intensity | 1 (Reference) | 1 (Reference) | ||
| Myeloabrative | 0.76 (0.44-1.31) | .328 | 0.93 (0.52-1.67) | .819 |
| WBC at diagnosis | ||||
| <30 000/μL | 1 (Reference) | 1 (Reference) | ||
| ≤30 000/μL | 1.04 (0.78-1.38) | .810 | 1.03 (0.94-1.14) | .468 |
| GVHD profiraxis | ||||
| CyA/MTX | 1 (Reference) | 1 (Reference) | ||
| Tacrorimus/MTX | 1.19 (0.89-1.60) | .250 | 1.23 (0.84-1.81) | .287 |
| Cytogenetics | ||||
| t(9;22) only | 1 (Reference) | 1 (Reference) | ||
| Other abnormality | 1.03 (0.68-1.54) | .900 | NA | |
| ABO blood type disparity | ||||
| Match | 1 (Reference) | 1 (Reference) | ||
| Minor | 1.31 (0.89-1.92) | .170 | NA | |
| Major | 1.28 (0.91-1.82) | .160 | NA | |
CyA, cyclospoline; NA, not applicable; RR, relative risk.